George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, VA 20110, USA.
Mol Oncol. 2010 Dec;4(6):461-81. doi: 10.1016/j.molonc.2010.09.003. Epub 2010 Oct 16.
Individualizing cancer therapy for molecular targeted inhibitors requires a new class of molecular profiling technology that can map the functional state of the cancer cell signal pathways containing the drug targets. Reverse phase protein microarrays (RPMA) are a technology platform designed for quantitative, multiplexed analysis of specific phosphorylated, cleaved, or total (phosphorylated and non-phosphorylated) forms of cellular proteins from a limited amount of sample. This class of microarray can be used to interrogate tissue samples, cells, serum, or body fluids. RPMA were previously a research tool; now this technology has graduated to use in research clinical trials with clinical grade sensitivity and precision. In this review we describe the application of RPMA for multiplexed signal pathway analysis in therapeutic monitoring, biomarker discovery, and evaluation of pharmaceutical targets, and conclude with a summary of the technical aspects of RPMA construction and analysis.
个体化癌症治疗的分子靶向抑制剂需要一类新的分子分析技术，该技术可以绘制包含药物靶点的癌细胞信号通路的功能状态图。反相蛋白微阵列（RPMA）是一种专为定量、多重分析来自有限样本量的特定磷酸化、切割或总（磷酸化和非磷酸化）形式的细胞蛋白而设计的技术平台。这类微阵列可用于检测组织样本、细胞、血清或体液。RPMA 以前是一种研究工具；现在，这项技术已经在具有临床级灵敏度和精度的临床研究试验中得到应用。在这篇综述中，我们描述了 RPMA 在治疗监测、生物标志物发现和药物靶点评估中的多重信号通路分析中的应用，并总结了 RPMA 构建和分析的技术方面。
